Leukemia· 2019Q1· Review
Targeting FLT3 mutations in AML: review of current knowledge and evidence
- 1,084citations
- Q1SCImago
- 2019year
Short summary
FLT3 mutations, particularly FLT3-ITD (in ~25% of AML cases), are common drivers associated with poor prognosis in acute myeloid leukemia, necessitating testing at diagnosis and relapse for targeted therapy.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine